on Friday that sided with the anti-abortion groups and overturned the FDA's decisions about mifepristone. His decision was immediately appealed by the Department of Justice.a group of pharmaceutical executives and companiesurging the appellate court to block the preliminary injunction and allow the FDA's approval of mifepristone to remain in place.
Late Wednesday night, the 5th Circuit dialed back the original preliminary injunction, saying that it was too late to challenge the FDA's 23-year-old original approval of mifepristone. "Industry members are wondering, well, if a judge can do that, what else can't a judge, perhaps with an ax to grind, do?" he saidBringing new drugs to market is already expensive and time-consuming. To research and develop a new medical product can cost hundreds of millions of dollars and years of clinical trials.
Take vaccines as an example, said Allison Whelan, a law professor at Georgia State University."This is essentially saying, 'Here is a way that you could stop these vaccines that you disagree with,' not for safety and efficacy reasons, but for other reasons," she said.